Related Experiment Video
Updated: Nov 19, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
1.0K
[COVID-19: Coagulopathy and thrombosis].
1Service médecine interne - hématologie clinique, hôpital Ibn Sina, Rabat, Maroc; Faculté de médecine et de pharmacie, université Mohammed VI, Rabat, Maroc.
La Revue De Medecine Interne
|January 29, 2021
Summary
Severe COVID-19 causes dangerous blood clotting issues, increasing mortality risk. Understanding these hemostatic disorders is crucial for effective anticoagulation strategies and patient survival.
Area of Science:
- Virology and Infectious Diseases
- Hematology and Coagulation Disorders
Background:
- The SARS-CoV-2 virus rapidly caused a global pandemic.
- Severe COVID-19 is frequently associated with significant coagulation abnormalities, such as elevated D-dimers.
- These COVID-19-associated coagulopathies correlate with a higher risk of mortality and can lead to unrecognized venous thromboembolic complications.
Purpose of the Study:
- To deepen the understanding of COVID-19 pathophysiology, focusing on hemostatic disorders.
- To guide the selection of appropriate treatment strategies for COVID-19 patients.
- To emphasize the need for rigorous thrombotic risk assessment and tailored anticoagulation.
Main Methods:
- Review of COVID-19 coagulation laboratory findings in affected patients.
- Analysis of the incidence and specific characteristics of thromboembolic events in COVID-19.
- Evaluation of potential therapeutic interventions for managing coagulopathy.
Main Results:
- Detailed characterization of laboratory findings indicative of coagulopathy in severe COVID-19.
- Quantification of the occurrence of venous thromboembolic events and their unique features.
- Identification of key aspects for therapeutic interventions.
Conclusions:
- A comprehensive understanding of COVID-19-induced hemostatic disorders is essential for clinical management.
- Implementing robust thrombotic risk assessment and appropriate anticoagulation is critical for improving outcomes.
- Further research into pathophysiology and therapeutic strategies is warranted.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
01:24Disorders of Hemostasis
1.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.6K
01:09Coagulation
8.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.8K
01:06Coagulation
634
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
634
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
01:30Venous Thrombosis I: Introduction
121
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
121